Cancer
Conditions
Keywords
unusual toxicity, radiosensitivity, radiotherapy, fibroblast cell, indirect immunofluorescence test
Brief summary
In order to evaluate the physiopathological knowledge of the different pathological manifestations associated with individual radiosensitivity, it seems essential to carry out this pilot study. It has agglomerated homogeneous tissue samples to identify new biomarkers for patient diagnosis and follow-up, and may predict the therapeutic response. These knowledge will help to treatment customization.
Interventions
OTHERskin biopsy
skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G).
OTHERtumor biopsy
an additional tumor sample will be taken during programmed diagnostic procedure.
OTHERblood sample
blood sample will be taken for biological collection
Sponsors
Institut de Cancérologie de Lorraine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Child or teenager aged 2 to \<18 * Man, Woman\> 18 years old * Patient with one of these situations: * Unusual toxicity in progress or after radiotherapy * Indication of radiotherapy and suspicion of abnormal pathways of response to ionizing radiation - constitutional (genetic disease) or acquired (systemic disease) - which may generate unusual radioinduced toxicity * Patient information and informed consent signed by the patient. For children and teenager : information to parents and obtaining informed consent * Affiliation to a social security scheme.
Exclusion criteria
* Contraindication for skin and / or tumoral biopsy * Contraindication for blood sample of 2.5 ml * Persons deprived of liberty or under supervision
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| skin fibroblast radiosensitivity | 2 to 3 months after skin biopsy | The number of residual double strand break at 24 hours (number of 53BP1 foci) after a dose of 2 Gy will be quantified with indirect immunofluorescence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| tumor cells radiosensitivity | 2 to 3 months after tumor biopsy | The number of residual double strand break at 24 hours (number of 53BP1 foci) after a dose of 2 Gy will be quantified with indirect immunofluorescence |
Countries
France
Outcome results
None listed